It is expected to control hypertension with one shot in half a year!

On November 8, 2021, Alnylam Pharmaceuticals announced the initiation of a global phase 2 clinical trial to evaluate RNAi therapy zilebesiran (formerly ALN-AGT) in hypertensive patients whose blood pressure cannot be adequately controlled by standard antihypertensive drug therapy.

Hypertension is a complex multi-factor disease.

RNAi (RNA interference) is a natural cellular process of gene silencing, and the discovery of it won the 2006 Nobel Prize in Physiology or Medicine

Zilebesiran is an RNAi therapy targeting mRNA that expresses angiotensinogen

▲Zilebesiran's mechanism of action (picture source: Alnylam official website)

This randomized, double-blind, placebo-controlled Phase 2 clinical trial will enroll approximately 800 adult hypertensive patients who have previously received standard antihypertensive medications

Reference materials:

[1] Alnylam Initiates KARDIA-2 Phase 2 Study of Investigational Zilebesiran (ALN-AGT) in Patients with Inadequately Controlled Hypertension.